| Literature DB >> 34367961 |
Zhen Tan1,2,3,4, Yubin Lei1,2,3,4, Bo Zhang1,2,3,4, Si Shi1,2,3,4, Jiang Liu1,2,3,4, Xianjun Yu1,2,3,4, Jin Xu1,2,3,4, Chen Liang1,2,3,4.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most invasive solid malignancies. Immunotherapy and targeted therapy confirmed an existing certain curative effect in treating PDAC. The aim of this study was to develop an immune-related molecular marker to enhance the ability to predict Stages III and IV PDAC patients.Entities:
Keywords: CIBERSORT; WGCNA; bioinformatics; immunocytes infiltration; pancreatic ductal adenocarcinoma
Year: 2021 PMID: 34367961 PMCID: PMC8343184 DOI: 10.3389/fonc.2021.674897
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Flowchart presenting the process of establishing the gene signature in this study.
Figure 2Selection of the appropriate beta value to construct a hierarchical cluster number. (A) Selected genes with Coefficient of variation values greater than 0.15. (B) Estimate fraction of immune cells by CIBERSORT algorithm in GSE16515. (C) Analysis of the scale-free fit index and of the average connectivity of 1–20 soft threshold power. (D) Genes are grouped into diverse modules by hierarchical clustering. Different colors represent different modules.
Figure 3Key modules and feature notes. (A) Heatmap and Eigengene-dendrogram show the correlations of module eigengenes with T-cell infiltration. (B) The first 20 enriched terms are shown as a bar chart on the left. The protein–protein interaction networks diagram on the right is constructed with each enrichment term as a node and which colored by different cluster ID.
Figure 4Identification of hub genes. (A) PPI network of top 100 genes was selected from the pink module. (B) A scatter plot of the genes in the pink module. (C) Hub genes were selected according to the overlap between PPI and pink module in co-expression networks.
Figure 5A four-gene signature system was established to predict the overall survival of Stages III and IV PDAC patients in the TCGA discovery and two independent validation cohorts. (A, B) LASSO coefficient profiles of the 62 immune-related’ genes. LASSO, least absolute shrinkage and selection operator method. (C) The expression level of the risk score in mutation status of TP53 in Stages III and IV PDAC patients of TCGA dataset. (D) The expression level of the risk score in mutation status of KRAS in Stages III and IV PDAC patients of TCGA dataset. (E) The Kaplan–Meier plot of 5-year overall survival in TCGA Stages III and IV PDAC cohort. (F) The Kaplan–Meier plot of 5-year overall survival in ICGC Stages III and IV PDAC cohort. (G) The Kaplan–Meier plot of 5-year overall survival in FUSCC Stages III and IV PDAC cohort.
Figure 6NAPSB, ZNF831, CXCL9 and PYHIN1 associated with CD4+ T lymphocyte infiltration and immunosuppression markers. (A) The Timer web tool was performed to estimate the association between the expression levels of four genes with the infiltration level of CD4+ T immune cells in PDAC samples. (B) Correlation between four-gene expression and PD1 and PDL1 in PDAC samples of TCGA dataset. Top of Scatter plots depicts R2 and p-values. (C) Correlation between four-gene expression and PD1 and PDL1 in PDAC samples of ICGC dataset. (D) Correlation between four-gene expression and PD1 and PDL1in PDAC samples of FUSCC dataset.
Figure 7The expression and clinical significance of gene signature in PDAC. (A–D) Expression of four genes in tumor and adjacent normal tissues from a cohort of 42 PDAC patients was determined by qPCR. (E) Forest plot summary of multivariable Cox regression analyses of the risk score, age, gender and grade on TCGA cohort. The squares represent the hazard ratio (HR), and the transverse lines represent 95% CI. CI, confidence interval. (F) A nomogram to predict survival probability at 3-year for PDAC patients based on the results deriving from the TCGA cohort. (G) Calibration curve for the nomogram when predicting 3-year overall survival.